Table 1 –
Characteristics of the overall cohort of patients (n = 2364)
| Age, median (IQR) | 61 (56–66) |
| Charlson comorbidity score, n (%) | |
| 0 | 1910 (81) |
| 1 | 234 (10) |
| ≥2 | 220 (9) |
| PSA, median (IQR) | 5.6 (4.1–8.1) |
| Nerve-sparing, n (%) | |
| None | 33 (1.4) |
| Unilateral | 78 (3.3) |
| Bilateral | 2253 (95.3) |
| Gleason grade, n (%) | |
| 1 | 336 (14.2) |
| 2 | 1297 (54.9) |
| 3 | 503 (21.3) |
| 4 | 111 (4.7) |
| 5 | 117 (4.9) |
| pT stage, n (%) | |
| pT2 | 1360 (57.5) |
| pT3 | 968 (41) |
| pT4 | 36 (1.5) |
| Positive surgical margins, n (%) | 408 (17) |
| Surgical approach, n (%) | |
| Open | 614 (26) |
| Laparoscopic | 633 (27) |
| Robotic | 1117 (47) |
| Rates of adjuvant/salvage treatment (%) a | |
| 1 yr | 8 |
| 2 yr | 11 |
IQR = interquartile range; PSA = prostate-specific antigen.
a
Estimated with Kaplan-Meier analysis